There was a variety of practice settings and deprescribing focuses (i.e., potentially inappropriate medications, benzodiazepines, opioids) in the included studies. These differences may limit the applicability of findings to specific practice sites or medication classes. Nevertheless, the findings of this study highlight that structural changes such as advancing pharmacist scope of practice, redesigning renumeration models, integrating healthcare systems and improving the data sharing are required to optimize pharmacist's role in deprescribing.
Bolt et al. (Thu,) studied this question.